Key result
Repeated intracoronary infusions of autologous bone marrow mononuclear cells in a patient with dilated cardiomyopathy improved left ventricular ejection fraction from 24% to 45% and reduced heart failure symptoms.
Why the study?
Does intracoronary infusion of autologous bone marrow mononuclear cells improve symptoms and left ventricular function in a patient with dilated cardiomyopathy?
Case Report (n=1)
No
Does intracoronary infusion of autologous bone marrow mononuclear cells improve symptoms and left ventricular function in a patient with dilated cardiomyopathy?
Repeated intracoronary infusions of autologous bone marrow mononuclear cells may provide long-term symptomatic and functional improvement in patients with severe dilated cardiomyopathy.
We present a 13-years follow-up results in patient with dilated cardiomyopathy. We performed intracoronary infusion of bone marrow mononuclear fraction in patient with 4th heart failure functional class in 2005. We observed an improvement in symptoms (patient had 1st functional class of heart failure) during 10-years follow-up. In 2015 due to clinical worsening we performed 2nd and 3rd bone marrow mononuclear cells infusion with 9-month interval. We observed a signifcant improvement in symptoms, EF and LV sizes. We continue the follow-up.
No takes yet. Share an insight, caveat, or question.
Beliy et al. (2019) conducted a case report in Dilated cardiomyopathy (n=1). Autologous bone marrow mononuclear cells was evaluated on Left ventricular ejection fraction and heart failure symptoms. Repeated intracoronary infusions of autologous bone marrow mononuclear cells in a patient with dilated cardiomyopathy improved left ventricular ejection fraction from 24% to 45% and reduced heart failure symptoms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: